OTTAWA, CANADA, November 15, 2024 – Genomadix (genomadix.com), a global leader in point of need
precision medicine diagnostics, announced today that it has entered into a know-how license agreement with
Mayo Clinic to collaborate on the delivery of enhanced telestroke services in the U.S.

Under the terms of the agreement, Mayo Clinic will grant Genomadix access to its specialized knowledge and
technical expertise in the telestroke space, collaborating with Genomadix to expand the use of its FDA-cleared
Genomadix Cube CYP2C19 System into sites in which stroke care is delivered, in part, remotely. 

Based on polymerase chain reaction (PCR) technology, the Cube can generate accurate CYP2C19 genotype test
results in around one hour, assisting clinicians in quickly making personalized dual-antiplatelet therapy (DAPT)
treatment decisions for stroke and cardiology patients. The availability of rapid CYP2C19 genotyping in a
telestroke setting is even more relevant since the American Heart Association published in June 2024 a Scientific
Statement on CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy, with relevance to both cardiology and
stroke.

“This agreement represents a significant benefit for both organizations,” said Steve Edgett, CEO of Genomadix.
“With the know-how and expertise of Mayo Clinic, Genomadix aims to deliver rapid CYP2C19 genotype results
helping guide therapeutic decisions for more patients in more locations.”

About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The
Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine
genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability
enables users to generate time-critical results in approximately one hour. The Cube platform is also available as
an open platform (CubeX) that can be used to design, develop and run any qPCR test for research or product
development purpose. Applications of the Genomadix Cube technology include, but are not limited to, precision
medicine, clinical diagnostics and environmental testing. For more information, visit www.genomadix.com.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any
revenue it receives to support its not-for-profit mission in patient care, education and research.

Media contact: Tara Linseman, Sr. Manager of Product Management

[email protected] +1-613-228-775